Table 1

Characteristics of lung cancer patients recruited to GELCAPS


Cases
Controls

Total
5,269
2,094
Gender (Male: Female)
3,382 (64.2%)
645 (30.8%)
Age at diagnosis (years)
887 (35.8%)
446 (69.1%)
     <40
53 (1.0%)
64 (3.1%)
     40–49
302 (5.7%)
166 (7.9%)
     50–59
1,146 (21.7%)
514 (24.5%)
     60–69
1,868 (35.4%)
756 (36.1%)
     70–79
1,590 (30.1%)
510 (24.4%)
     80+
310 (5.9%)
84 (4.0%)
     Mean (SD)
65.1 (10.0)
62.9 (10.6)
Ethnicity


     Arabic
3 (0.05%)
1 (0.05%)
     Asian
7 (0.13%)
6 (0.29%)
     Bangladeshi
1 (0.01%)
0
     Black-African
4 (0.08%)
1 (0.05%)
     Black-Caribbean
31 (0.59%)
8 (0.38%)
     Black-Other
1 (0.01%)
0
     Indian
16 (0.30%)
4 (0.19%)
     Jewish-Ashkenazi
12 (0.22%)
6 (0.29%)
     Pakistani
8 (0.15%)
0
     White
5,065 (96.1%)
1,947 (93.0%)
     Other/not specified
82 (1.6%)
121 (5.8%)
Reported asbestos exposure
807 (15.2%)
125 (6.0%)
Family history of lung cancer
750 (14.2%)
212 (10.1%)
Smoking habits


     Never-smokers
307 (5.8%)
718 (34%)
     All smokers


     Age first started smoking (SD)
16.5 (4.0)
17.9 (4.8%)
     Pack years in Smokers (SD)
47.2 (30.6)
30.4 (22.1%)



Histology of cancer


Small cell (SCLC)
1,193 (22.6%)

Non-small cell (NSCLC)
3,815 (72.4%)

     Squamous
1,905 (49.9%)

     Adenocarcinoma (including variants)
1,110 (29.1%)

     Large cell
10 (0.3%)

     Brochoalveolar
44 (1.2%)

     Adenosquamous
11 (0.3%)

     Neuroendocrine
20 (0.5%)

     NSCLC unspecified
715 (18.7%)

Sarcoma
5 (0.1%)

Unclassified primary
256 (4.9%)




Tumour stage at presentation, by histology


     SCLC


          Limited
168 (50.4%)

          Extensive
165 (59.6%)

     NSCLC


          I
151 (14.1%)

          II
140 (13.1%)

          III
457 (42.7%)

          IV
323 (30.2%)


Eisen et al. BMC Cancer 2008 8:244   doi:10.1186/1471-2407-8-244